Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Inhibition of p38 MAP kinase increases okadaic acid mediated AP-1 expression and DNA binding but has no effect on TRE dependent transcription

Abstract

By performing in vitro kinase assays we found in papilloma producing 308 mouse keratinocytes that okadaic acid elevated activities of extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinases (MAPKs). This okadaic acid mediated activation of MAP kinases correlated with increased AP-1 binding to a consensus TPA responsive element (TRE) and elevated TRE dependent transcription. To determine the role of p38 MAP kinases in these processes we employed the specific p38 MAP kinase inhibitor SB 203580. Using orthophosphate labeling we showed a decrease in phosphorylation of MAPK activated protein kinase-2 (MAPKAP-K2) indicating reduced activity of p38 MAPKs utilizing this kinase as substrate. In contrast, we found that SB 203580 raised activities of ERK-1/2 and JNKs. Electrophoretic mobility shift assays revealed an increase in TRE binding activity in response to SB 203580 most likely resulting from increased expression of the major TRE binding components JunD and FosB as indicated by Western blot analyses. Increased TRE DNA binding failed to lead to increased transactivation correlating with the inability of SB 203580 to increase phosphorylation of these AP-1 proteins. These data indicate that SB 203580 sensitive p38 MAP kinases are not involved in okadaic acid mediated increases in TRE DNA binding and transactivation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Bernstein LR, Bravo R and Colburn NH. . 1989 Science 244: 566–569.

  • Bialojan C and Takai A. . 1988 Biochem. J. 256: 283–290.

  • Chu Y, Solski PA, Khosravi-Far R, Der CJ and Kelly K. . 1996 J. Biol. Chem. 271: 6497–6501.

  • Cuenda A, Cohen P, Buee-Scherrer V and Goedert M. . 1997 EMBO J. 16: 295–305.

  • Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR and Lee JC. . 1995 FEBS Lett. 364: 229–233.

  • Daum G, Kalmes A, Levkau B, Wang Y, Davies MG and Clowes AW. . 1998 FEBS Lett. 427: 271–274.

  • Dignam JD, Lebovitz RM and Roeder RG. . 1983 Nucleic Acids Res. 11: 1475–1489.

  • Domann FE, Levy JP, Birrer MJ and Bowden GT. . 1994 Cell Growth Differ. 5: 9–16.

  • Dong Z, Huang C, Brown RE and Ma WY. . 1997a J. Biol. Chem. 272: 9962–9970.

  • Dong Z, Ma W, Huang C and Yang CS. . 1997b Cancer Res. 57: 4414–4419.

  • Dong Z, Crawford HC, Lavrovsky V, Taub D, Watts R, Matrisian LM and Colburn NH. . 1997c Mol. Carcinog. 19: 204–212.

  • Dong Z, Watts RG, Sun Y, Zhan SN and Colburn NH. . 1995 Int. J. Oncology 7: 359–364.

  • Dong Z, Birrer MJ, Watts RG, Matrisian LM and Colburn NH. . 1994 Proc. Natl. Acad. Sci. USA 91: 609–613.

  • Goedert M, Cuenda A, Craxton M and Jakes R. . 1997 EMBO J. 16: 3563–3571.

  • Gum R, Wang H, Lengyel E, Juarez J and Boyd D. . 1997 Oncogene 14: 1481–1493.

  • Haystead TAJ, Sim ATR, Carling D, Honnor RC, Tsukitani Y, Cohen P and Hardie DG. . 1989 Nature 337: 78–81.

  • Hazzalin CA, Cano E, Cuenda A, Barratt MJ, Cohen P and Mahadevan LC. . 1996 Curr. Biol. 6: 1028–1031.

  • Hazzalin CA, Cuenda A, Cano E, Cohen P and Mahadevan LC. . 1997 Oncogene 15: 2321–2331.

  • Honkanen RE, Zwiller J, Daily SL, Khatra BS, Dukelow M and Boynton AL. . 1991 J. Biol. Chem. 266: 6614–6619.

  • Huang C, Ma W-Y, Young MR, Colburn NH and Dong Z. . 1998 Proc. Natl. Acad. Sci. USA 95: 156–161.

  • Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA and Dong Z. . 1997 Proc. Natl. Acad. Sci. USA 94: 5826–5830.

  • Karin M, Liu ZG and Zandi E. . 1997 Curr. Opin. Cell Biol. 9: 240–246.

  • Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC and Young PR. . 1997 Biochem. Biophys. Res. Comm. 235: 533–538.

  • Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL and Young PR. . 1994 Nature 372: 739–746.

  • Li J-J, Dong Z, Dawson MI and Colburn NH. . 1996 Cancer Res. 56: 483–489.

  • Ludwig S, Hoffmeyer A, Goebeler M, Kilian K, Häfner H, Neufeld B, Han J and Rapp UR. . 1998 J. Biol. Chem. 273: 1917–1922.

  • Marshall CJ. . 1995 Cell 80: 179–185.

  • Murata M, Shimatani M, Sugitani H, Oshima Y and Yasumoto T. . 1982 Bull. Japanese Soc. Fisheries 48: 549–552.

  • Nikolakaki E, Coffer PJ, Hemelsoet R, Woodgett JR and Defize LHK. . 1993 Oncogene 8: 833–840.

  • Rosenberger SF, Finch JS, Gupta A and Bowden GT. . 1999 J. Biol. Chem. 274: 1124–1130.

  • Rosenberger SF and Bowden GT. . 1996 Oncogene 12: 2301–2308.

  • Ryseck RP and Bravo R. . 1991 Oncogene 6: 533–542.

  • Sassa T, Richter WW, Uda N, Suganuma M, Suguri H, Yoshizawa S, Hiroto M and Fujiki H. . 1989 Biochem. Biophys. Res. Commun. 159: 939–944.

  • Schliess F, Heinrich S and Haussinger D. . 1998 Arch. Biochem. Biophys. 351: 35–40.

  • Sheikh-Hamad D, Di Mari J, Suki WN, Safirstein R, Watts III BA and Rouse D. . 1998 J. Biol. Chem. 273: 1832–1837.

  • Skinner M, Qu S, Moore C and Wisdom R. . 1997 Mol. Cell. Biol. 17: 2372–2380.

  • Strickland JE, Greenhalgh DA, Koceva-Chyla A, Hennings H, Restrepo C, Balaschak M and Yuspa SH. . 1988 Cancer Res. 48: 165–169.

  • Suganuma M, Fujiki H, Suguri H, Yoshizawa S, Hirota M, Nakayasu M, Ojika M, Wakamatsu K, Yamada K and Sugimura T. . 1988 Proc. Natl. Acad. Sci. USA 85: 1768–1771.

  • Tachibana K, Scheuer PJ and Tsukitani Y. . 1981 J. Am. Chem. Soc. 103: 2469–2471.

  • Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, Brown ML and Pargellis CA. . 1998 Nat. Struct. Biol. 4: 311–316.

  • Wang H, Xie Z and Scott RE. . 1996 Oncogene 13: 2639–2647.

  • Watts RG, Ben-Ari ET, Bernstein LR, Birrer MJ, Winterstein D, Wendel E and Colburn NH. . 1995 Mol. Carcinog. 13: 27–36.

  • Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME. . 1995 Science 270: 1326–1331.

  • Yuspa SH. . 1998 J. Dermatol. Sci. 17: 1–7.

Download references

Acknowledgements

We would like to thank Dr Stuart Yuspa for providing the cell line 308 and Drs Powel Brown and Li Min Yang for the TRE luciferase construct. We would also like to thank Smith Kline Beecham for SB 203580. This work was supported in part by National Cancer Institute grant CA 40584 as well as Cancer Center Core Grant CA 23074 and Toxicology Center Grant NIEMS p30-ESO 6694 awarded to GTB.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenberger, S., Gupta, A. & Bowden, G. Inhibition of p38 MAP kinase increases okadaic acid mediated AP-1 expression and DNA binding but has no effect on TRE dependent transcription. Oncogene 18, 3626–3632 (1999). https://doi.org/10.1038/sj.onc.1202695

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202695

Keywords

This article is cited by

Search

Quick links